RESUMEN
An HPLC/MS/MS method was validated for the low level analysis of pyridostigmine bromide (PB) from guinea pig plasma. An advantage of this strong-cation exchange HPLC/MS/MS method was the enhancement of the ESI-MS signal by providing good retention and good peak shape of PB with a mobile phase of 70% acetonitrile. In addition, the use of 70% acetonitrile in the mobile phase allowed the direct injection of the supernant from the protein precipitated extracted sample. The assay was linear from the range of 0.1 to 50 ng/ml using only 25 microl of sample. The precision and accuracy of the assay was better than 9.1 and 113%, respectively.
Asunto(s)
Inhibidores de la Colinesterasa/sangre , Cromatografía Líquida de Alta Presión/métodos , Bromuro de Piridostigmina/sangre , Espectrometría de Masa por Ionización de Electrospray/métodos , Animales , Cobayas , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
BACKGROUND: In support of bioanalysis, there has always been a desire to improve detection limits and reduce scale. Microflow LC (MFLC) coupled with MS accomplishes both of these goals. RESULTS: As such, MFLC coupled with an MS system was used to generate bioanalytical validation data that met US FDA criteria. The MFLC-MS/MS data was compared with the same method with the use of conventional HPLC-MS/MS and a more than 14× S/N improvement was found with the MFLC-MS/MS method. Methotrexate was used as a model molecule to demonstrate the validation of the method from human plasma. The MFLC-MS/MS method was demonstrated to be accurate (±7%) and precise (12.9% at the LLOQ and a maximum of 11.6% at all other concentrations) across the dynamic range of the assay (1-1000 ng/ml) and compared well with the HPLC-MS/MS method. The MFLC bioanalytical validation was performed at a flow rate of 35 µl/min on a 0.5-mm inner diameter (I.D.) column, whereas, for the same linear velocities on the 2.0-mm I.D. column, the conventional HPLC bioanalytical validation was performed at 700 µl/min. Since the flow rate of the MFLC system is 20-times less than the HPLC system, the consumable solvent and disposal cost to perform the MFLC validation was significantly less. CONCLUSION: MFLC-MS/MS can be used to perform bioanalytical method validations with increased MS signal, reduced source contamination and reduced solvent consumption.
Asunto(s)
Antimetabolitos Antineoplásicos/sangre , Cromatografía Líquida de Alta Presión/métodos , Metotrexato/sangre , Espectrometría de Masas en Tándem/métodos , Cromatografía Líquida de Alta Presión/instrumentación , Diseño de Equipo , Humanos , Límite de Detección , Espectrometría de Masas en Tándem/instrumentaciónRESUMEN
DBS techniques for the bioanalysis of drugs and metabolites from whole blood have been demonstrated to be a useful tool in drug development. The term dried matrix spot (DMS) has been used to indicate that the DBS technique has been applied to nonblood matrices. DMS methods often employ a color-indicating process that enhances the ability to analyze these mostly transparent fluids when spotted onto collection paper. The color-indicating dye allows the analyst to visually confirm the location of the dried sample spot. Other benefits of using a color-indicating dye include improved method accuracy and precision, because the process of adding the dye allows for the concurrent addition of the IS prior to sample addition and extraction. To date, matrices that have been analyzed using DMS include cerebrospinal fluid, synovial fluid, saliva, tears, urine and plasma.
Asunto(s)
Colorantes/normas , Desecación/instrumentación , Saliva/química , Líquido Sinovial/química , Lágrimas/química , Animales , Dexametasona/análisis , Humanos , Ratas , Estándares de Referencia , Reproducibilidad de los Resultados , Robótica , Sensibilidad y Especificidad , Manejo de Especímenes , PorcinosRESUMEN
BACKGROUND: Conventional liquid-handling devices were employed, along with an improved punching device, to semi-automate dried blood spot (DBS) extraction of alprazolam, α-hydroxyalprazolam and midazolam from human whole blood. Liquid-handling devices were used to add internal standard to the DBS cards and to extract the analytes from the DBS, in order to be analyzed by HPLC-MS/MS. RESULTS: The technique was shown to be accurate (±12.0%) and precise (10.3%) across the dynamic range of the assay. CONCLUSION: The semi-automated extraction reduced sample preparation time by more than 50% when compared with more conventional DBS manual extraction methods.
Asunto(s)
Cromatografía Líquida de Alta Presión , Pruebas con Sangre Seca/métodos , Espectrometría de Masas en Tándem , Alprazolam/análogos & derivados , Alprazolam/sangre , Automatización , Pruebas con Sangre Seca/instrumentación , Humanos , Midazolam/sangreRESUMEN
BACKGROUND: Dried matrix spot techniques were employed to validate an HPLC-MS/MS assay for the determination of dexamethasone in clear Yorkshire pig synovial fluid using 15 µl of sample. We have adopted the term dried matrix spot to indicate that the techniques used for dried blood spots can be applied to nonblood matrices. The dried matrix spot method employs a color-indicating process developed at Alturas Analytics that enhances the ability to analyze transparent fluids spotted onto collection paper by allowing the analyst to visually verify the location of the dried sample spot. RESULTS: The method was shown to be accurate (±4.3%) and precise (14.2% at the LLOQ and ≤10.0% at all other concentrations) across the dynamic range of the assay. CONCLUSION: The method shows the potential application of dried matrix spot techniques for the analysis of transparent biological fluids.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Dexametasona/análisis , Manejo de Especímenes/métodos , Porcinos , Líquido Sinovial/química , Espectrometría de Masas en Tándem/métodos , Animales , Color , Colorantes/química , Dexametasona/aislamiento & purificación , Estabilidad de Medicamentos , Estándares de Referencia , Espectrometría de Masas en Tándem/normasRESUMEN
BACKGROUND: Two ESI-LC-MS/MS methods were validated for the quantitative analysis of loxapine, amoxapine, 7-OH-loxapine, 8-OH-loxapine and loxapine N-oxide in human K(2)EDTA plasma. Cation-exchange solid-phase extraction (SPE) was used to extract loxapine, amoxapine and the two hydroxylated metabolites, and organic precipitation was used to quantify loxapine N-oxide. RESULTS: Both methods were shown to be accurate (±13%), intra-assay precision was less than 15%, and inter-assay precision was less than 10% in all instances across the entire dynamic range of the assays (0.0500-50.0 ng/ml for the SPE method and 0.100-25.0 ng/ml for the precipitation method). CONCLUSION: The validated methods for loxapine, amoxapine, 7-OH-loxapine, 8-OH-loxapine and loxapine N-oxide have been used to successfully support clinical trials.